Last reviewed · How we verify

Agenus Inc. — Portfolio Competitive Intelligence Brief

Agenus Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 3 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
HSPPC-96 or Oncophage HSPPC-96 or Oncophage phase 3 Autologous therapeutic cancer vaccine Tumor-associated antigens presented via Hsp96 complexes Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Advaxis, Inc. · 1 shared drug class
  2. European Organisation for Research and Treatment of Cancer - EORTC · 1 shared drug class
  3. Fundacion Clinic per a la Recerca Biomédica · 1 shared drug class
  4. Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · 1 shared drug class
  5. Merck KGaA, Darmstadt, Germany · 1 shared drug class
  6. National Cancer Institute (NCI) · 1 shared drug class
  7. TD Vaccines A/S · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Agenus Inc.:

Cite this brief

Drug Landscape (2026). Agenus Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/agenus-inc. Accessed 2026-06-10.

Related